- Home
- KALV
as 11-07-2024 4:00pm EST
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 523.1M | IPO Year: | N/A |
| Target Price: | $29.00 | AVG Volume (30 days): | 247.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.21 - $16.88 | Next Earning Date: | 12-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 539.64% |
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Sep 6 '24 | Sell | $12.19 | 7,352 | $89,621.62 | 250,800 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Aug 22 '24 | Sell | $12.40 | 1,916 | $23,758.40 | 85,676 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Aug 22 '24 | Sell | $12.40 | 2,135 | $26,474.00 | 83,745 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Aug 17 '24 | Sell | $12.01 | 14,215 | $170,769.06 | 250,800 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Aug 17 '24 | Sell | $12.01 | 7,102 | $85,318.46 | 85,676 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Aug 17 '24 | Sell | $12.01 | 7,973 | $95,782.04 | 83,745 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
KalVista Secures $184M Financing for Sebetralstat Launch
Business Wire
3 days ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 days ago
KalVista Closes Royalty Financing Deal with DRI Healthcare, Prices $55 Million Offering
MT Newswires
4 days ago
DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat
Business Wire
4 days ago
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
Business Wire
4 days ago
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
Business Wire
11 days ago
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
Business Wire
21 days ago
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Compare KALV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.